Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10507607 | 0.85 | MEN1 (0.31) | MEN1CYP2C9KMT2A | |
| SCHEMBL9171769 | 0.83 | TRIM24 (0.44) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| Ethylene SCHEMBL15565158 | 0.81 | — | — | |
| SCHEMBL307414 | 0.80 | — | — | |
| SCHEMBL16099106 | 0.80 | TRIM24 (0.41) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL16877327 | 0.76 | TTR (0.42) | ALDH1A1TSHR | |
| SCHEMBL1701084 | 0.76 | MEN1 (0.34) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL2558905 | 0.76 | ESR2 (0.35) | KDM4EL3MBTL1 | |
| SCHEMBL5110848 | 0.75 | TRIM24 (0.44) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL136359 | 0.75 | TRIM24 (0.44) | MEN1CYP2C9KMT2ATRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010139717-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | claimed |
| US-20260053792-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2026-02-26 | — | — | US | disclosed |
| EP-4563575-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-119816489-A | Polysubstituted tetrahydroisoquinoline compound, preparation method, pharmaceutical composition and application | 中国科学院上海药物研究所 | 2025-04-11 | — | — | CN | disclosed |
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2024255765-A1 | NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024022528-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 中国科学院上海药物研究所 | 2024-02-01 | — | — | WO | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230150986-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-05-18 | — | — | US | disclosed |
| US-8765763-B2 | Substituted piperazines as CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| WO-2010139717-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139717-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-7439263-B2 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1598350-B1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | SERVIER LAB (FR) | 2007-07-11 | — | — | EP | disclosed |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
| EP-1598350-A1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | LES LABORATOIRES SERVIER (FR) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | KDM4E 393/4885L3MBTL1 317/4885MEN1 762/4885 |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | CALCR, CALCRL, P2RX5 | KDM4E 3075/4885L3MBTL1 4788/4885MEN1 1573/4885 |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | DPP4, DPP3, NR4A1 | KDM4E 812/4885L3MBTL1 3009/4885MEN1 3591/4885 |
| US-20260053792-A1 | POLYSUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | TFEB, SNCA, PARK7 | KDM4E 2547/4885L3MBTL1 917/4885MEN1 4817/4885 |
| US-20230150986-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | KDM4E 2282/4885L3MBTL1 2482/4885MEN1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.